---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-043844"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2026-09-23T13:21:42+00:00"
generated_at: "2026-09-23T13:23:12.229874+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Glucotrack (Lōkahi) advances LT-100, submits protocol; ai² platform flags 45 assets

## Summary
- Completed strategic business combination on July 14, 2026; Glucotrack Technologies now wholly owned subsidiary.
- LT-100 for osteoarthritis knee pain: clinical protocol submitted for regulatory review; targeting near-term study start.
- Planned study evaluates once-weekly subcutaneous injection vs historical 15 weekly intradermal injections.
- ai² platform has 14 university partners, screening 12,000+ abandoned late-stage programs; 45 assets met initial criteria.
- Qare first ai² Accelerator initiative; business model aims to monetize assets before registration trials.

## SEC filing metadata
- accession: 0001493152-26-043844
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2026-09-23T13:21:42+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315226043844/0001493152-26-043844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315226043844/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-043844
- JSON: https://secwatch.observer/filing/0001493152-26-043844.json
- Plain text: https://secwatch.observer/filing/0001493152-26-043844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.